Published in Adv Drug Deliv Rev on March 15, 2010
Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med (2012) 1.35
Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther (2011) 1.29
Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine (2012) 1.27
Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA (2013) 1.24
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Aptamer in bioanalytical applications. Anal Chem (2011) 1.21
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
Imaging of nucleic acids with atomic force microscopy. Methods (2011) 1.13
Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine (2011) 1.13
Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells. Nat Protoc (2013) 1.11
Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano (2011) 1.06
Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods (2011) 1.03
In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano (2011) 0.99
Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int (2013) 0.92
Neutral polymeric micelles for RNA delivery. Bioconjug Chem (2013) 0.86
RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. Biomed Res Int (2015) 0.85
Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA. Sci Rep (2015) 0.84
Nanolayered siRNA dressing for sustained localized knockdown. ACS Nano (2013) 0.84
Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release (2014) 0.83
microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2. Lab Invest (2015) 0.82
Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine (2015) 0.82
Computational prediction of efficient splice sites for trans-splicing ribozymes. RNA (2012) 0.82
High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin Drug Deliv (2013) 0.82
Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy. PLoS One (2015) 0.81
Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv Drug Deliv Rev (2016) 0.81
New paradigms on siRNA local application. BMB Rep (2015) 0.80
RNA modularity for synthetic biology. F1000Prime Rep (2013) 0.79
Optimized method for the synthesis and purification of adenosine--folic acid conjugates for use as transcription initiators in the preparation of modified RNA. Methods (2010) 0.79
Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int J Nanomedicine (2013) 0.78
The Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano (2017) 0.77
Nanogel star polymer architectures: a nanoparticle platform for modular programmable macromolecular self-assembly, intercellular transport, and dual-mode cargo delivery. Adv Mater (2011) 0.77
siRNA Targeting the 2Apro Genomic Region Prevents Enterovirus 71 Replication In Vitro. PLoS One (2016) 0.77
Differential baseline expression and angiotensin II-stimulation of leukemia-associated RhoGEF in vascular smooth muscle cells of spontaneously hypertensive rats. Int J Nanomedicine (2012) 0.76
Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market. J Chem Biol (2012) 0.76
Enhanced stability and knockdown efficiency of poly(ethylene glycol)-b-polyphosphoramidate/siRNA micellar nanoparticles by co-condensation with sodium triphosphate. Pharm Res (2011) 0.76
Evaluation of end-capped DNA modules for pRNA capture and functionalization. Bioconjug Chem (2012) 0.75
Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat Commun (2017) 0.75
Local administration of siRNA through Microneedle: Optimization, Bio-distribution, Tumor Suppression and Toxicity. Sci Rep (2016) 0.75
Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA. Int J Nanomedicine (2016) 0.75
Expression of short hairpin RNAs using the compact architecture of retroviral microRNA genes. Nucleic Acids Res (2017) 0.75
Chitosan-Mediated shRNA Knockdown of Cytosolic Alanine Aminotransferase Improves Hepatic Carbohydrate Metabolism. Mar Biotechnol (NY) (2016) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
RNA interference. Nature (2002) 22.28
On finding all suboptimal foldings of an RNA molecule. Science (1989) 20.36
A species of small antisense RNA in posttranscriptional gene silencing in plants. Science (1999) 19.34
The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 15.26
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell (1982) 12.12
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell (1987) 8.19
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Self-splicing of group I introns. Annu Rev Biochem (1990) 6.36
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Antisense RNA inactivation of myosin heavy chain gene expression in Dictyostelium discoideum. Science (1987) 6.13
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell (2000) 5.18
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 4.49
Metals, motifs, and recognition in the crystal structure of a 5S rRNA domain. Cell (1997) 4.46
RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol (2006) 4.38
New approaches to nanofabrication: molding, printing, and other techniques. Chem Rev (2005) 4.33
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 4.06
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A (2005) 3.78
Barriers to drug delivery in solid tumors. Sci Am (1994) 3.57
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
cis elements and trans-acting factors involved in dimer formation of murine leukemia virus RNA. J Virol (1990) 3.40
Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev (2005) 3.39
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science (1987) 3.29
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science (1991) 3.18
Nanotechnology. Thin solid films roll up into nanotubes. Nature (2001) 3.09
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature (1992) 3.02
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Evolutionary perspective on the structure and function of ribonuclease P, a ribozyme. J Bacteriol (1995) 2.82
Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc (2005) 2.80
Autocatalytic cyclization of an excised intervening sequence RNA is a cleavage-ligation reaction. Nature (1983) 2.79
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev (1990) 2.75
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 2.68
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem (1994) 2.66
Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst (1989) 2.62
RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther (2006) 2.59
Fibronectin extension and unfolding within cell matrix fibrils controlled by cytoskeletal tension. Proc Natl Acad Sci U S A (2002) 2.43
Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem (1993) 2.34
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res (2007) 2.30
siRNA and innate immunity. Oligonucleotides (2009) 2.28
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol (2003) 2.26
Lipid-based nanoparticles for nucleic acid delivery. Pharm Res (2007) 2.25
Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci U S A (2005) 2.23
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev (2009) 2.21
Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A (2004) 2.21
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans (2007) 2.19
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Cell biology of viruses that assemble along the biosynthetic pathway. Semin Cell Biol (1992) 2.16
Chemically modified siRNA: tools and applications. Drug Discov Today (2008) 2.13
Nobel Prize in Physiology or Medicine. Method to silence genes earns loud praise. Science (2006) 2.09
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol (2004) 1.98
Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology. Nano Lett (2004) 1.91
All you wanted to know about SELEX. Mol Biol Rep (1994) 1.88
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther (2006) 1.86
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
A novel immune system against bacteriophage infection using complementary RNA (micRNA). Nature (1985) 1.85
Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther (2005) 1.81
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
RNA pseudoknots: structure, detection, and prediction. Methods Enzymol (1989) 1.75
In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res (2004) 1.75
RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol (2005) 1.68
Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res (2004) 1.67
Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc (2005) 1.66
Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology (2009) 2.24
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol (2011) 2.09
Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology (2007) 1.80
Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today (2012) 1.39
Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther (2011) 1.29
Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano (2010) 1.21
Crystal structure of 3WJ core revealing divalent ion-promoted thermostability and assembly of the Phi29 hexameric motor pRNA. RNA (2013) 1.14
Binding of pRNA to the N-terminal 14 amino acids of connector protein of bacteriophage phi29. Nucleic Acids Res (2005) 1.12
General anesthetics induce apoptotic neurodegeneration in the neonatal rat spinal cord. Anesth Analg (2008) 1.09
Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther (2007) 1.04
Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. Antiviral Res (2009) 1.01
Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. Mol Ther (2010) 1.00
Scalable fabrication of high-performance and flexible graphene strain sensors. Nanoscale (2014) 0.97
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods (2011) 0.97
Fabrication of massive sheets of single layer patterned arrays using lipid directed reengineered phi29 motor dodecamer. ACS Nano (2009) 0.95
Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano (2015) 0.92
Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. ACS Nano (2015) 0.91
An ultra-high element density pMUT array with low crosstalk for 3-D medical imaging. Sensors (Basel) (2013) 0.83
Synthesis, conjugation, and labeling of multifunctional pRNA nanoparticles for specific delivery of siRNA, drugs, and other therapeutics to target cells. Methods Mol Biol (2012) 0.83
Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine (2007) 0.81
Dynamics of nutritional status in dying patients with acute cerebral infarction in central China: a preliminary study. Neurol Res (2011) 0.80
Chemical mapping of ceramide distribution in sphingomyelin-rich domains in monolayers. Langmuir (2008) 0.79
Crystallization of Phi29 spindle-shaped nano-bar anti-receptor with glycosidase domain. J Nanosci Nanotechnol (2007) 0.78
A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. Vaccine (2009) 0.78
A novel flexible capacitive touch pad based on graphene oxide film. Nanoscale (2012) 0.77
Candidate-gene exclusion in a family with inherited non-syndromic dental disorders. Gene (2012) 0.77
Notch Signaling Augments BMP9-Induced Bone Formation by Promoting the Osteogenesis-Angiogenesis Coupling Process in Mesenchymal Stem Cells (MSCs). Cell Physiol Biochem (2017) 0.76
Engineering the Rapid Adenovirus Production and Amplification (RAPA) Cell Line to Expedite the Generation of Recombinant Adenoviruses. Cell Physiol Biochem (2017) 0.75
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? J Neurooncol (2015) 0.75
Methods and assays for specific targeting and delivery of RNA nanoparticles to cancer metastases. Methods Mol Biol (2015) 0.75
[The genetic stability of non-replicating recombinant adenoviruses on 293 cells during continuous passage]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2008) 0.75
[The safety of bronchoscope guided implantation of 2 double-lumen balloon micro-catheter in the treatment of pulmonary hemoptysis: the factors involved]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue (2011) 0.75
Craniocervical pneumatization presenting as cranial nerve IX-XII palsies: case report and review of the literature. Neurol India (2015) 0.75
Laser directed lithography of asymmetric graphene ribbons on a polydimethylsiloxane trench structure. Phys Chem Chem Phys (2013) 0.75
[Improved expression of human rotavirus G1VP7 and G3VP7 antigens in the recombinant adenoviruses by codon optimization]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2008) 0.75
[Clinical and imaging features of adult anoxic-ischemic encephalopathy after cardiopulmonary resuscitation]. Zhonghua Yi Xue Za Zhi (2012) 0.75
[Tal1 promotes proliferation of acute lymphoblastic leukemia Jurkat cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao (2016) 0.75
[Preparation, characterization, and pulmonary delivery of rifapentine liposomes modified by lauric diethanolamide]. Yao Xue Xue Bao (2006) 0.75
[Effects of Epstein-Barr virus and cytomegalovirus infection on childhood acute lymphoblastic leukemia gene methylation]. Nan Fang Yi Ke Da Xue Xue Bao (2013) 0.75
Hepatoprotective effects of triterpenoids from Ganoderma cochlear. J Nat Prod (2014) 0.75